How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

16,120 results for

Methotrexate

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Methotrexate for psoriatic arthritis. Full Text available with Trip Pro

Methotrexate for psoriatic arthritis. Psoriatic arthritis is an inflammatory disease associated with joint damage, impaired function, pain, and reduced quality of life. Methotrexate is a disease-modifying anti-rheumatic drug (DMARD) commonly prescribed to alleviate symptoms, attenuate disease activity, and prevent progression of disease.To assess the benefits and harms of methotrexate for psoriatic arthritis in adults.We searched CENTRAL, MEDLINE, Embase, the WHO International Clinical Trials (...) Registry Platform, and www.clinicaltrials.gov for relevant records. We searched all databases from inception to 29 January 2018. We handsearched included articles for additional records and contacted study authors for additional unpublished data. We applied no language restrictions.We included all randomised controlled trials (RCTs) and quasi-RCTs that compared methotrexate versus placebo, or versus another DMARD, for adults with psoriatic arthritis. We reported on the following major outcomes: disease

2019 Cochrane

2. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate Full Text available with Trip Pro

Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate Early initiation of effective treatment favours remission in rheumatoid arthritis, but it remains unknown if the same concept applies to psoriatic arthritis (PsA). Therefore, this study investigated whether the combination of golimumab plus methotrexate (MTX) as a first-line treatment is superior

2019 EvidenceUpdates

3. Using subcutaneous methotrexate to prolong duration of methotrexate therapy in rheumatoid arthritis Full Text available with Trip Pro

Using subcutaneous methotrexate to prolong duration of methotrexate therapy in rheumatoid arthritis Our study aims to determine whether the use of subcutaneous methotrexate (SC MTX) is associated with prolonged MTX use and lower incidence of hepatotoxicity in rheumatoid arthritis (RA) patients on MTX monotherapy and multiple drug therapy.We conducted a retrospective cohort study using national databases of a large hospital system. Subjects had been diagnosed with RA and treated with MTX between

2018 European journal of rheumatology

4. Efficacy and safety of long-term baricitinib with and without methotrexate for the treatment of rheumatoid arthritis: experience with baricitinib monotherapy continuation or after switching from methotrexate monotherapy or baricitinib plus methotrexate. (Abstract)

Efficacy and safety of long-term baricitinib with and without methotrexate for the treatment of rheumatoid arthritis: experience with baricitinib monotherapy continuation or after switching from methotrexate monotherapy or baricitinib plus methotrexate. To evaluate the long-term efficacy and safety of maintaining baricitinib monotherapy in patients with active rheumatoid arthritis (RA) originally treated with baricitinib monotherapy or switched from methotrexate (MTX) or the combination

2019 Arthritis care & research Controlled trial quality: uncertain

5. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with Full Text available with Trip Pro

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with Prevention of graft-versus-host disease (GvHD) without malignant relapse is the overall goal of allogeneic haemopoietic cell transplantation (HCT). We aimed to evaluate regimens using either maraviroc, bortezomib, or post-transplantation (...) cyclophosphamide for GvHD prophylaxis compared with controls receiving the combination of tacrolimus and methotrexate using a novel composite primary endpoint to identify the most promising intervention to be further tested in a phase 3 trial.In this prospective multicentre phase 2 trial, adult patients aged 18-75 years who received reduced-intensity conditioning HCT were randomly assigned (1:1:1) by random block sizes to tacrolimus, mycophenolate mofetil, and post-transplantation cyclophosphamide

2019 The Lancet. Haematology Controlled trial quality: predicted high

6. Injectable methotrexate and ectopic pregnancy. An alternative to surgery, but patients must be made aware of the risks

Injectable methotrexate and ectopic pregnancy. An alternative to surgery, but patients must be made aware of the risks Prescrire IN ENGLISH - Spotlight ''Injectable methotrexate and ectopic pregnancy. An alternative to surgery, but patients must be made aware of the risks'', 1 February 2018 {1} {1} {1} | | > > > Injectable methotrexate and ectopic pregnancy. An alternative to surgery, but patients must be made aware of the risks Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 (...) most recent :  |   |   |   |   |   |   |   |   |  Spotlight Injectable methotrexate and ectopic pregnancy. An alternative to surgery, but patients must be made aware of the risks FEATURED REVIEW For some women with an ectopic pregnancy, intramuscular injection of methotrexate can be an alternative to surgery. But methotrexate carries the risks of a cytotoxic drug, and is teratogenic: women treated with methotrexate should wait

2018 Prescrire

7. EMA reviewing risk of dosing errors with methotrexate

EMA reviewing risk of dosing errors with methotrexate EMA reviewing risk of dosing errors with methotrexate | European Medicines Agency Search Search Menu EMA reviewing risk of dosing errors with methotrexate Press release 13/04/2018 Review prompted by continued reports of overdose The European Medicines Agency (EMA) has started a review of the risk of dosing errors with methotrexate medicines. When used for inflammatory diseases, such as arthritis and psoriasis, methotrexate is taken once (...) a week whereas for some types of cancer, the dose is higher and the medicine is used more frequently. Mistakes have led to some patients incorrectly receiving a dose every day instead of every week. As a result, patients have received too much of the medicine, with serious consequences in some cases. The risk of dosing errors with methotrexate has been recognised for many years and several measures are already in place in some EU countries to reduce this risk, including the use of visual reminders

2018 European Medicines Agency - EPARs

8. Tofacitinib (Xeljanz) - in combination with methotrexate for the treatment of active psoriatic arthritis in adult patients

Tofacitinib (Xeljanz) - in combination with methotrexate for the treatment of active psoriatic arthritis in adult patients 1 Published 14 January 2019 1 SMC2116 tofacitinib, 5mg film-coated tablet (Xeljanz®) Pfizer UK 7 December 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission (...) tofacitinib (Xeljanz®) is accepted for restricted use within NHSScotland. Indication under review: in combination with methotrexate for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy. SMC restriction: for use in patients with psoriatic arthritis whose disease has not responded adequately to at least two conventional DMARDs, given either alone or in combination. Two

2019 Scottish Medicines Consortium

9. Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate. Full Text available with Trip Pro

Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate. Methotrexate is considered to be first-line therapy for rheumatoid arthritis (RA). However, a substantial proportion of treated patients do not achieve the desired goals of therapy. This analysis aimed to identify predictors of insufficient response to methotrexate (...) in patients with early RA.The Optimal Protocol for Treatment Initiation with Methotrexate and Adalimumab (OPTIMA) and PREMIER studies in patients with RA for <1 and <3 years, respectively, examined the efficacy of methotrexate and adalimumab in methotrexate-naive patients. This post hoc analysis included patients for whom initial methotrexate monotherapy was not successful after 6 months. Candidate predictors of insufficient response and clinically relevant radiographic progression (CRRP) included

2018 Annals of the Rheumatic Diseases Controlled trial quality: uncertain

10. Associating adalimumab with methotrexate decreases uveitis associated with juvenile idiopathic arthritis

Associating adalimumab with methotrexate decreases uveitis associated with juvenile idiopathic arthritis Associating adalimumab with methotrexate decreases uveitis associated with juvenile idiopathic arthritis - Evidencias en pediatría Searching, please wait Show menu Library Management You did not add any article to your library yet. | Search Evidence-Based decision making Evidence-Based decision making Show menu Library Management You did not add any article to your library yet. × User (...) Password Log in × Reset password If you need to reset your password please enter your email and click the Send button. You will receive an email to complete the process. Email Send × Library Management × September 2017. Volume 13. Number 3 Associating adalimumab with methotrexate decreases uveitis associated with juvenile idiopathic arthritis Rating: 0 (0 Votes) Reviewers: , . | Newsletter Free Subscription Regularly recieve most recent articles by e-mail Subscribe × Newsletter subscription: Email

2017 Evidencias en Pediatría

11. Methotrexate (Jylamvo)

Methotrexate (Jylamvo) 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 26 January 2017 EMA/78284/2017 Committee for Medicinal Products for Human Use (CHMP) Assessment report Jylamvo International non-proprietary name: methotrexate (...) of Suitability of the EP EDQM European Directorate for the Quality of Medicines GC gas chromatography ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use LDPE low density polyethylene MTX methotrexate 7-OHMTX 7-hydroxymethotrexate RA rheumatoid arthritis JIA juvenile idiopathic arthritis PEG polyethylene glycol Ph. Eur. European Pharmacopoeia RH relative humidity SmPC Summary of Product Characteristics TAMC Total Aerobic Microbial Count

2017 European Medicines Agency - EPARs

12. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Full Text available with Trip Pro

Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Sarilumab is a human immunoglobulin G1 anti-interleukin-6 (IL-6) receptor monoclonal antibody that blocks IL-6 from binding to membrane-bound and soluble IL-6 receptor α. This bridging study assessed the efficacy and safety of sarilumab + methotrexate (MTX) in Japanese patients with active rheumatoid arthritis (RA

2019 Arthritis research & therapy Controlled trial quality: predicted high

13. Live Zoster Vaccine in Patients with Rheumatoid Arthritis Treated with Tofacitinib with or without Methotrexate, or Adalimumab with Methotrexate. Full Text available with Trip Pro

Live Zoster Vaccine in Patients with Rheumatoid Arthritis Treated with Tofacitinib with or without Methotrexate, or Adalimumab with Methotrexate. To explore herpes zoster (HZ) rates, and live zoster vaccine (LZV) safety, in a subset of patients with rheumatoid arthritis (RA) who received LZV before tofacitinib ± methotrexate (MTX), or adalimumab (ADA) + MTX, in ORAL Strategy.ORAL Strategy (NCT02187055) was a 1-year, Phase 3b/4, randomized triple-dummy, active-comparator-controlled study. MTX

2019 Arthritis care & research Controlled trial quality: uncertain

14. Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-I (Abstract)

Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-I Methotrexate (MTX), often combined with low moderately dosed prednisone, is still the cornerstone of initial treatment for early rheumatoid arthritis (RA). It is not known how this strategy compares with initial treatment with a biological. We

2019 Annals of the Rheumatic Diseases

15. Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen. Full Text available with Trip Pro

Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen. Children with Down syndrome and acute lymphoblastic leukemia often suffer from severe toxicities during treatment, especially with high-dose methotrexate. Systematic data on methotrexate toxicity in these patients are rare. We analyzed seven methotrexate-associated toxicities during consolidation therapy (...) in 103 Down-syndrome- and 1,109 Non-Down-syndrome-patients with acute lymphoblastic leukemia enrolled in ALL-BFM trials between 1995-2016 and 1995-2007, respectively. Patients received four courses methotrexate (5 g/m2 each) plus intrathecal methotrexate and 6-mercaptopurine. From 2004 on, a dose of 0.5 g/m2 in the 1st methotrexate course was recommended for Down-syndrome-patients. Down-syndrome-patients showed higher rates of 3/4 toxicities after the 1st course with 5 g/m2 methotrexate compared

2019 Haematologica

16. Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Full Text available with Trip Pro

Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Following publication of the original article [1], the authors reported an error in Table 2.

2019 Arthritis research & therapy Controlled trial quality: uncertain

17. Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. Full Text available with Trip Pro

Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. In MOBILITY (NCT01061736), sarilumab significantly reduced disease activity, improved physical function and inhibited radiographic progression at week 52 versus placebo in patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate. We report 5-year safety, efficacy and radiographic outcomes (...) of sarilumab from NCT01061736 and the open-label extension (EXTEND; NCT01146652), in which patients received sarilumab 200 mg every 2 weeks (q2w) + methotrexate.Patients (n=1197) with moderately to severely active RA were initially randomised to placebo, sarilumab 150 mg or sarilumab 200 mg subcutaneously q2w plus weekly methotrexate for 52 weeks. Completers were eligible to enrol in the open-label extension and receive sarilumab 200 mg q2w + methotrexate.Overall, 901 patients entered the open-label

2019 RMD open Controlled trial quality: uncertain

18. Low-dose Methotrexate has Similar Outcomes to High-dose Methotrexate in Combination with Anti-TNF Therapy in Inflammatory Bowel Diseases. (Abstract)

Low-dose Methotrexate has Similar Outcomes to High-dose Methotrexate in Combination with Anti-TNF Therapy in Inflammatory Bowel Diseases. Methotrexate [MTX] is a well-known immunomodulator in the treatment of inflammatory bowel disease [IBD] and is often combined with biologic agents. The ideal MTX dose for combination therapy has not been determined. This study aimed to investigate the effect of varying doses of MTX on efficacy and safety outcomes when used with anti-TNF agents in IBD.This

2019 Journal of Crohn's & colitis

19. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. (Abstract)

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the comparative efficacy of tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus (...) methotrexate for the treatment of rheumatoid arthritis in patients with a previous inadequate response to methotrexate.ORAL Strategy was a 1 year, double-blind, phase 3b/4, head-to-head, non-inferiority, randomised controlled trial in patients aged 18 years or older with active rheumatoid arthritis despite methotrexate therapy. Patients were randomly assigned (1:1:1) to receive oral tofacitinib (5 mg twice daily) monotherapy, oral tofacitinib (5 mg twice daily) plus methotrexate, or subcutaneous adalimumab

2017 Lancet Controlled trial quality: predicted high

20. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom

Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>